Patents Assigned to Mycomagic Biotechnology Co., Ltd.
-
Patent number: 12180506Abstract: The present disclosure provides a method for proliferating or propagating undifferentiated stem cells, comprising contacting a population of stem cells with an effective amount of Ganoderma immunomodulatory protein or a recombinant thereof or a fragment thereof.Type: GrantFiled: April 20, 2021Date of Patent: December 31, 2024Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Michael Lee
-
Patent number: 12122809Abstract: The present disclosure relates to a method for alleviating and/or treating a coronavirus disease in a subject in need thereof, including administering an effective amount of Ganoderma immunomodulatory protein, a recombinant thereof or a fragment thereof to the subject.Type: GrantFiled: January 12, 2023Date of Patent: October 22, 2024Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventors: Tung-Yi Lin, Hsin Yeh, Zhi-Hu Lin
-
Patent number: 11141458Abstract: The present disclosure provides compositions comprising Ganoderma immunomodulatory protein or a recombinant thereof and a gel-forming agent. Also provided are methods for the treatment of chronic wounds, ulcers or sores, and methods using the compositions.Type: GrantFiled: July 17, 2019Date of Patent: October 12, 2021Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventors: Hsu-Yuan Fu, Yu-Che Cheng
-
Patent number: 11077168Abstract: The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in reducing damage caused by fine particulate matter on embryos and offspring. Accordingly, the present invention suggests that the Ganoderma immunomodulatory protein administrated to pregnant animals can prevent neurological damages and reduce risk of disorders in embryos and offspring.Type: GrantFiled: April 3, 2018Date of Patent: August 3, 2021Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTDInventor: Ming Wei Chao
-
Patent number: 11058746Abstract: The present invention provides a method of preventing or treating fibrosis in a subject, comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma lucidum, Ganoderma lucidum, Ganoderma tsugae, Ganoderma microsporum or Ganoderma sinensis to the subject, thereby preventing or treating a fibrosis.Type: GrantFiled: September 25, 2017Date of Patent: July 13, 2021Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Cheng-Chia Yu
-
Patent number: 9975931Abstract: The inventors surprisingly found that an immunomodulatory protein from Ganoderma can promote neurite outgrowth, suggesting that the immunomodulatory protein from Ganoderma can treat and/or prevent neurological disorders. Accordingly, the invention provides a method for promoting neurite outgrowth, the method comprising exposing the neuron to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof. The invention also provides a method for treating and/or preventing a neurological disorder, the method comprising administering an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof to a subject.Type: GrantFiled: October 20, 2015Date of Patent: May 22, 2018Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Ming-Wei Chao
-
Patent number: 9937226Abstract: The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in inhibiting cancel stem cells. Particularly, the immunomodulatory protein is derived form Ganoderma microsporum and the cancel stem cell is oral cancer stem cell.Type: GrantFiled: December 29, 2015Date of Patent: April 10, 2018Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Cheng-Chia Yu
-
Patent number: 9827288Abstract: The present invention relates to a method for treating a refractory or relapsed lung cancer. Particularly, the invention provides a method and a formulation of using an immunomodulatory protein derived from Ganoderma microsporum in the treatment of a refractory or relapsed lung cancer.Type: GrantFiled: September 21, 2015Date of Patent: November 28, 2017Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventors: Hsien-Yeh Hsu, Tung-Yi Lin
-
Patent number: 9528093Abstract: The invention provides a recombinant polynucleotide comprising a truncated glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter and a modified HBV S protein gene and a transgenic Flammulina velutipes carrying the recombinant polynucleotide. The invention surprisingly found that after administering the transgenic Flammulina velutipes to a subject, the subject can successfully generate an antibody against HBV. Therefore, the transgenic Flammulina velutipes can be used as a vaccine against HBV.Type: GrantFiled: August 21, 2014Date of Patent: December 27, 2016Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Ying-Tzu Lyu
-
Publication number: 20160051664Abstract: The invention provides a recombinant polynucleotide comprising a truncated glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter and a modified HBV S protein gene and a transgenic Flammulina velutipes carrying the recombinant polynucleotide. The invention surprisingly found that after administering the transgenic Flammulina velutipes to a subject, the subject can successfully generate an antibody against HBV. Therefore, the transgenic Flammulina velutipes can be used as a vaccine against HBV.Type: ApplicationFiled: August 21, 2014Publication date: February 25, 2016Applicant: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Ying-Tzu Lyu
-
Patent number: 9163250Abstract: The invention found that partial deletion of the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter can enhance gene expression (even heterologous gene expression) in basidiomycetous fungi. With the discovery of these gpd promoters, an expression system can be constructed for the expression of a heterologous gene in mushroom. Accordingly, the invention provides a truncated glyceraldehyde-3-phosphate dehydrogenase promoter and a construct comprising the promoter of the invention operably linked to a heterologous transcribable polynucleotide molecule and a mushroom comprising the construct.Type: GrantFiled: October 26, 2012Date of Patent: October 20, 2015Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Ying-Tzu Lyu
-
Patent number: 9161964Abstract: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.Type: GrantFiled: May 8, 2013Date of Patent: October 20, 2015Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Jiunn-Liang Ko
-
Patent number: 9018171Abstract: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.Type: GrantFiled: November 14, 2013Date of Patent: April 28, 2015Assignee: Mycomagic Biotechnology Co., Ltd.Inventor: Jiunn-Liang Ko
-
Publication number: 20140123345Abstract: The invention found that partial deletion of the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter can enhance gene expression (even heterologous gene expression) in basidiomycetous fungi. With the discovery of these gpd promoters, an expression system can be constructed for the expression of a heterologous gene in mushroom. Accordingly, the invention provides a truncated glyceraldehyde-3-phosphate dehydrogenase promoter and a construct comprising the promoter of the invention operably linked to a heterologous transcribable polynucleotide molecule and a mushroom comprising the construct.Type: ApplicationFiled: October 26, 2012Publication date: May 1, 2014Applicant: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Ying-Tzu Lyu
-
Publication number: 20140086946Abstract: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.Type: ApplicationFiled: November 14, 2013Publication date: March 27, 2014Applicant: Mycomagic Biotechnology Co., Ltd.Inventor: JIUNN-LIANG KO
-
Patent number: 8476238Abstract: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.Type: GrantFiled: June 29, 2010Date of Patent: July 2, 2013Assignee: Mycomagic Biotechnology Co., Ltd.Inventor: Jiunn-Liang Ko
-
Publication number: 20110318429Abstract: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.Type: ApplicationFiled: June 29, 2010Publication date: December 29, 2011Applicant: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Jiunn-Liang Ko
-
Patent number: 7973215Abstract: The invention develops a simple and reliable mushroom transformation procedure on the basis of electroporation of spores or mycelial fragments of mushroom.Type: GrantFiled: April 11, 2008Date of Patent: July 5, 2011Assignee: Mycomagic Biotechnology Co., Ltd.Inventor: Chun-Yi Kuo
-
Patent number: 7777021Abstract: The invention relates to discovery of an isolated glyceraldehyde-3-phosphate dehydrogenase promoter in Pleurotus and a construct comprising the promoter of the invention operably linked to a heterologous transcribable polynucleotide molecule.Type: GrantFiled: January 28, 2008Date of Patent: August 17, 2010Assignee: Mycomagic Biotechnology Co., Ltd.Inventor: Chun-Yi Kuo
-
Patent number: 7759100Abstract: The present invention pertains to a polynucleotide sequence expressed in Flammulina velutipes against carboxin and the proteins encoded thereby. Also provided is the expression vector and host cell comprising the polynucleotides of the invention.Type: GrantFiled: December 2, 2008Date of Patent: July 20, 2010Assignee: Mycomagic Biotechnology Co., Ltd.Inventor: Hsiu-Hsin Hsieh